We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca (AZ) has agreed to pay Chugai Pharmaceutical $775 million to resolve allegations that AZ’s rare disease immunotherapy, Ultomiris (ravulizumab), infringed on the Tokyo-based company’s patents. Read More
Alnylam Pharmaceuticals is suing both Pfizer and Moderna in separate suits, alleging that both companies’ COVID-19 vaccines infringe on one of Alnylam patents for technology that allows RNA-based therapeutics or vaccines to be delivered safely into the body. Read More
Gilead Sciences has become the 15th major drugmaker to limit its involvement with the 30-year-old 340B Drug Discount Program that was designed to serve low-income patient populations in the U.S. Read More
The FDA approved Evrysdi to treat patients two months and older with Type 1 spinal muscular atrophy in August 2020, making it the first oral drug approved to treat the disease. Read More
The FDA has approved the first generic version of AstraZeneca’s Symbicort, a blockbuster drug-device combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Read More
The FDA is asking its vaccines advisory committee to meet next month to make a recommendation on Pfizer’s and BioNTech’s March 15 request to amend its Emergency Use Authorization (EUA) for approval of a fourth shot/second booster of its COVID-19 vaccine Comirnaty for people age 65 and older. Read More
Patients treated with Aduhelm experienced decreased levels of tau — the second dysregulated protein in Alzheimer’s disease — which were associated with a slowing of cognitive decline, Biogen executive Samantha Budd Haeberlein said yesterday at the AD/PD 2022 meeting on Alzheimer’s disease and Parkinson’s disease in Barcelona, Spain, March 15-20. Read More